Search Results - "George, Sarah L."

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5‐year follow‐up of 150 patients by George, Sarah L., Bacon, Bruce R., Brunt, Elizabeth M., Mihindukulasuriya, Kusal L., Hoffmann, Joyce, Di Bisceglie, Adrian M.

“…One hundred fifty patients with sustained virologic response (SVR) after treatment of chronic hepatitis C were enrolled in a long‐term clinical follow‐up…”
Get full text

GB Virus C Replicates in Primary T and B Lymphocytes by George, Sarah L., Varmaz, Dino, Stapleton, Jack T.

“…GB virus C (GBV-C) infection is common in humans and may persist for decades, although most infected persons clear the virus and subsequently develop…”
Get full text

The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+ T lymphocyte cell line without decreasing HIV receptor expression by George, Sarah L, Varmaz, Dino, Tavis, John E, Chowdhury, Adnan

“…Persistent infection with GBV-C (GB Virus C), a non-pathogenic virus related to hepatitis C virus (HCV), prolongs survival in HIV infection. Two GBV-C…”
Get full text

Mycobacterium ulcerans infection imported from Australia to Missouri, USA, 2012 by Thomas, Benjamin Stuart, Bailey, Thomas C, Bhatnagar, Julu, Ritter, Jana M, Emery, Brian D, Jassim, Omar W, Hornstra, Ian Kerst, George, Sarah L

“…Buruli ulcer, the third most common mycobacterial disease worldwide, rarely affects travelers and is uncommon in the United States. We report a…”
Get full text

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials by Modjarrad, Kayvon, Lin, Leyi, George, Sarah L, Stephenson, Kathryn E, Eckels, Kenneth H, De La Barrera, Rafael A, Jarman, Richard G, Sondergaard, Erica, Tennant, Janice, Ansel, Jessica L, Mills, Kristin, Koren, Michael, Robb, Merlin L, Barrett, Jill, Thompson, Jason, Kosel, Alison E, Dawson, Peter, Hale, Andrew, Tan, C Sabrina, Walsh, Stephen R, Meyer, Keith E, Brien, James, Crowell, Trevor A, Blazevic, Azra, Mosby, Karla, Larocca, Rafael A, Abbink, Peter, Boyd, Michael, Bricault, Christine A, Seaman, Michael S, Basil, Anne, Walsh, Melissa, Tonwe, Veronica, Hoft, Daniel F, Thomas, Stephen J, Barouch, Dan H, Michael, Nelson L

“…A safe, effective, and rapidly scalable vaccine against Zika virus infection is needed. We developed a purified formalin-inactivated Zika virus vaccine (ZPIV)…”
Get full text

CD8⁺ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate by Chu, Haiyan, George, Sarah L., Stinchcomb, Dan T., Osorio, Jorge E., Partidos, Charalambos D.

“…We are developing a live-attenuated tetravalent dengue vaccine (TDV) candidate based on an attenuated dengue 2 virus (TDV-2) and 3 chimeric viruses containing…”
Get full text

A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge by Parker, Scott, D'Angelo, June, Buller, R. Mark, Smee, Donald F., Lantto, Johan, Nielsen, Henriette, Jensen, Allan, Prichard, Mark, George, Sarah L.

“…Orthopoxviruses such as variola and monkeypox viruses continue to threaten the human population. Monkeypox virus is endemic in central and western Africa and…”
Get full text

Persistent GB Virus C Infection Is Associated with Decreased HIV-1 Disease Progression in the Amsterdam Cohort Study by George, Sarah L.

Get full text

Corticosteroid treatment in COVID‐19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation by Pinski, Amanda N., Steffen, Tara L., Zulu, Michael Z., George, Sarah L., Dickson, Alexandria, Tifrea, Delia, Maroney, Kevin J., Tedeschi, Neil, Zhang, Yun, Scheuermann, Richard H., Pinto, Amelia K., Brien, James D., Messaoudi, Ilhem

“…Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of coronavirus disease‐2019 (COVID‐19), a respiratory disease that varies…”
Get full text

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial by George, Sarah L., Wong, Mimi A., Dube, Tina J. T., Boroughs, Karen L., Stovall, Janae L., Luy, Betty E., Haller, Aurelia A., Osorio, Jorge E., Eggemeyer, Linda M., Irby-Moore, Sharon, Frey, Sharon E., Huang, Claire Y.-H., Stinchcomb, Dan T.

“…Background. Dengue viruses (DENVs) infect >300 million people annually, causing 96 million cases of dengue disease and 22 000 deaths [1]. A safe vaccine that…”
Get full text

Preclinical and clinical development of a dengue recombinant subunit vaccine by Manoff, Susan B, George, Sarah L, Bett, Andrew J, Yelmene, Michele L, Dhanasekaran, Govindarajan, Eggemeyer, Linda, Sausser, Michele L, Dubey, Sheri A, Casimiro, Danilo R, Clements, David E, Martyak, Timothy, Pai, Vidya, Parks, D. Elliot, Coller, Beth-Ann G

“…Highlights • DEN-80E formulated with ISCOMATRIX™ adjuvant is immunogenic in non-human primates. • A 0, 1, 6 month schedule results in higher antibody titers…”
Get full text

Synthesis of PtNi Nanoparticles to Accelerate the Oxygen Reduction Reaction by Leteba, Gerard M., George, Sarah L., Mitchell, David R. G., Levecque, Pieter B. J., Steen, Eric, Macheli, Lebohang, Lang, Candace I.

“…We report the synthesis of core‐shell Ni−Pt nanoparticles (NPs) with varying degrees of crystallographic facets and surface layers rich in Pt via a…”
Get full text

Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial by Potter, Gail E, Bonnett, Tyler, Rubenstein, Kevin, Lindholm, David A, Rapaka, Rekha R, Doernberg, Sarah B, Lye, David C, Mularski, Richard A, Hynes, Noreen A, Kline, Susan, Paules, Catharine I, Wolfe, Cameron R, Frank, Maria G, Rouphael, Nadine G, Deye, Gregory A, Sweeney, Daniel A, Colombo, Rhonda E, Davey, Jr, Richard T, Mehta, Aneesh K, Whitaker, Jennifer A, Castro, Jose G, Amin, Alpesh N, Colombo, Christopher J, Levine, Corri B, Jain, Mamta K, Maves, Ryan C, Marconi, Vincent C, Grossberg, Robert, Hozayen, Sameh, Burgess, Timothy H, Atmar, Robert L, Ganesan, Anuradha, Gomez, Carlos A, Benson, Constance A, Lopez de Castilla, Diego, Ahuja, Neera, George, Sarah L, Nayak, Seema U, Cohen, Stuart H, Lalani, Tahaniyat, Short, William R, Erdmann, Nathaniel, Tomashek, Kay M, Tebas, Pablo

“…The COVID-19 standard of care (SOC) evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear. To evaluate whether recovery and…”
Get full text

Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1α, MIP-1β, and SDF-1 by JINHUA XIANG, GEORGE, Sarah L, WÜNSCHMANN, Sabina, QING CHANG, KLINZMAN, Donna, STAPLETON, Jack T

Get full text

Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors by Chowdhury, Adnan Y, Tavis, John E, George, Sarah L

“…Abstract We previously found that human pegivirus (HPgV; formerly GBV-C) NS3 protease activity inhibits Human Immunodeficiency Virus (HIV) replication in a…”
Get full text

Prospects for a dengue vaccine: progress and pitfalls by George, Sarah L

“…Dengue virus is now the world's most common arboviral infection and has spread to the continental United States. The Aedes mosquito which transmits dengue is…”
Get full text

Chikungunya update by George, Sarah L

Get full text

Effect of Coinfection with GB Virus C on Survival among Patients with HIV Infection by Xiang, Jinhua, Wünschmann, Sabina, Diekema, Daniel J, Klinzman, Donna, Patrick, Kevin D, George, Sarah L, Stapleton, Jack T

“…GBV-C infection is common in people with HIV infection and is associated with significantly improved survival. The course of human immunodeficiency virus (HIV)…”
Get full text

Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections by Sweeney, Daniel A, Tuyishimire, Bonifride, Ahuja, Neera, Beigel, John H, Beresnev, Tatiana, Cantos, Valeria D, Castro, Jose G, Cohen, Stuart H, Cross, Kaitlyn, Dodd, Lori E, Erdmann, Nathan, Fung, Monica, Ghazaryan, Varduhi, George, Sarah L, Grimes, Kevin A, Hynes, Noreen A, Julian, Kathleen G, Kandiah, Sheetal, Kim, Hannah Jang, Levine, Corri B, Lindholm, David A, Lye, David C, Maves, Ryan C, Oh, Myoung-don, Paules, Catharine, Rapaka, Rekha R, Short, Willam R, Tomashek, Kay M, Wolfe, Cameron R, Kalil, Andre C

“…Abstract We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled…”
Get full text

Higher Antigen Content Improves the Immune Response to 2009 H1N1 Influenza Vaccine in HIV-Infected Adults: A Randomized Clinical Trial by El Sahly, Hana M., Davis, Charles, Kotloff, Karen, Meier, Jeffery, Winokur, Patricia L, Wald, Anna, Johnston, Christine, George, Sarah L., Brady, Rebecca C., Lehmann, Corinne, Stokes-Riner, Abbie, Keitel, Wendy A.

“…Background. The immunogenicity of a high hemagglutinin (HA) dose or a second dose of influenza vaccine in human immunodeficiency virus (HlV)-infected…”
Get full text